Abstract: A method of classifying kidney tumors is provided. The method includes obtaining a sample from a subject, isolating DNA from the sample, determining the methylation status of the DNA, and comparing the methylation status of the DNA to one or more methylated biomarkers selected from the following: cg04877910, cg09667289, cg05274650, cg11473616, cg16935734, cg27534624, cg21851713, cg15867829, cg15679829, cg08884979, cg09538401, cg26811868, cg05367028, cg19816080, cg20108357, cg25504868, cg11201447, cg19922137, cg14706317, cg15902830, cg10794973, cg10777887, cg03290131, cg07851269, cg11264947, cg00279406, cg23140965, cg03574652, cg03265671, cg24864241, cg01572891, cg00193963, cg14329285, cg17819990, cg17298239, cg23856138, cg21049501, cg11808936, cg25170591, cg17983632, cg08141142, cg19848599, cg25799109, cg07093324, cg16223546, cg07604732, cg12149606, cg08949329, cg27166177, cg26177041, cg09885851, cg22876153, cg21386992, cg02309772, cg02833180, cg20007890, cg04972244, cg02666955 and cg12102682.

Abstract: A method of identifying subjects having prostate cancer is provided. The method includes obtaining a sample from a subject, isolating DNA from the sample, determining the methylation status of the DNA, and comparing the methylation status of the DNA to one or more methylated probes selected from the following: cg00697992, cg01272707, cg01819167, cg01906055, cg02160684, cg02560085, cg03195164, cg03456213, cg04634417, cg06024295, cg11748187, cg13300630, cg13944838, cg14399930, cg15132013, cg16469740, cg17004353, cg17032646, cg18315943, cg19550524, cg20399616, cg24517686, cg25961816, cg26447413 and cg27198013. The comparison indicates whether the sample is normal, a non-aggressive prostate cancer, or an aggressive prostate cancer.

Abstract: A method of identifying subjects having prostate cancer is provided. The method includes obtaining a sample from a subject, isolating DNA from the sample, determining the methylation status of the DNA, and comparing the methylation status of the DNA to one or more methylated probes selected from the following: cg00697992, cg01272707, cg01819167, cg01906055, cg02160684, cg02560085, cg03195164, cg03456213, cg04634417, cg06024295, cg11748187, cg13300630, cg13944838, cg14399930, cg15132013, cg16469740, cg17004353, cg17032646, cg18315943, cg19550524, cg20399616, cg24517686, cg25961816, cg26447413 and cg27198013. The comparison indicates whether the sample is normal, a non-aggressive prostate cancer, or an aggressive prostate cancer.

Abstract: A method of classifying kidney tumors is provided. The method includes obtaining a sample from a subject, isolating DNA from the sample, determining the methylation status of the DNA, and comparing the methylation status of the DNA to one or more GO methylated biomarkers selected from the following: cg04877910, cg09667289, cg05274650, cg1 1473616, cg16935734, cg27534624, cg21851713, cg15867829, cg15679829, cg08884979, cg09538401, cg26811868, cg05367028, cg19816080, cg20108357, cg25504868, cg1 1201447, cg19922137, cg14706317, cg15902830, cg10794973, cg10777887, cg03290131, cg07851269, cg1 1264947, cg00279406, cg23140965, cg03574652, cg03265671, cg24864241, cg01572891, cg00193963, cg14329285, cg17819990, cg17298239, cg23856138, cg21049501, cg1 1808936, cg25170591, cg17983632, cg08141142, cg19848599, cg25799109, cg07093324, cg16223546, cg07604732, cg12149606, cg08949329, cg27166177, cg26177041, cg09885851, cg22876153, cg21386992, cg02309772, cg02833180, cg20007890, cg04972244, cg02666955 and cg12102682.